SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

por Nuijten, M, Mickisch, G
Publicado 2010

Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

por Nuijten, M, Mickisch, G
Publicado 2010

Reply: Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

por Mickisch, G H J, Escudier, B, Walzer, S, Nuijten, M
Publicado 2010

Immuntherapie und Tyrosinkinaseinhibitoren beim metastasierten Nierenzellkarzinom in der First-line-Therapie – Wann welche Strategie?

por Mickisch, G., Peters, I., Grüllich, C., Mudra, T., Doehn, C.
Publicado 2020

Erratum zu: Immuntherapie und Tyrosinkinaseinhibitoren beim metastasierten Nierenzellkarzinom in der First-line-Therapie – Wann welche Strategie?

por Mickisch, G., Peters, I., Grüllich, C., Mudra, T., Doehn, C.
Publicado 2021

Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib

por Mickisch, G, Gore, M, Escudier, B, Procopio, G, Walzer, S, Nuijten, M
Publicado 2010

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate can...

por Albrecht, W, Van Poppel, H, Horenblas, S, Mickisch, G, Horwich, A, Serretta, V, Casetta, G, Maréchal, J M, Jones, W G, Kalman, S, Sylvester, R
Publicado 2004